Skip to main content
MapleLMS Implementation
Conferences and Meetings 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster II

631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster II

Short name: 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster II
Course start date: 11/08/2025

Sections

General
0 activities

A Murine Model Presenting Leukemic Transformation from MPN with a Mutation in Epigenetic Modifier
Characteristics and Consequences of Platelets Derived from JAK2-Mutated Megakaryocytes
Chronic Kidney Dysfunction Induced By Jak2V617F-Mediated Mesangiolysis
Clinical and Molecular Characterization of Disease Progression in Patients (Pts) with Low-Risk Myelofibrosis (MF) Enrolled in the MOST Study
Evaluation of the Lethal Activity and Its Mechanism of Tasquinimod in Advanced Myeloproliferative Neoplasm (MPN) in Blastic Phase
Increased Thromboinflammation Is Associated with High Thrombotic Risk in Patients with Myeloproliferative Neoplasms: A Multicentric Study of 394 Cases By the French Intergroup of Myeloproliferative Neoplasms (FIM)
Interferon Alpha Activates the Unfolded Protein Response Resulting in Synergy with Bortezomib in JAK2 V617F Myeloproliferative Neoplasms
Molecular Predictors of Disease Progression to Myelofibrosis (MF) in Patients (Pts) with Polycythemia Vera (PV) Enrolled in Reveal
RUX-AZA Response in AP/BP-MPN Is Driven By Release of the Differentiation Block in Mutant HSPCs: A Single-Cell Multi-Omic Analysis of Responders on the Phase Ib Phazar Study
Reticulin-Free Quantitative Assessment of Bone Marrow Fibrosis in Myeloproliferative Neoplasms; Time to Sell the Family Silver?
Unveiling MED12L: A Potential Novel Orchestrator of Platelet Dysfunction in Myeloproliferative Myeloid Neoplasms